The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of December 2022, we identify the following current VC trends in the US-Biotech sector:
- In 2022, overall Biotech funding in the USA has reached USD 31,894m (-1,027m compared to 2021)
- The top 5 deals exceed USD 340m each, largest transaction amounted to USD 3,000m in Altos Labs
- ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by OrbiMed (USA) and RA Capital Management (USA)
- Oncology dominates as the top indication
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
Life Sciences Venture Capital Monitor – Europe 02/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 02/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
Life Sciences Venture Capital Monitor – Europe 01/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 01/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
FCF Biotech Venture Capital Monitor – USA 12/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 12/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Life Sciences Venture Capital Monitor – Europe 12/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 12/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
FCF Biotech Venture Capital Monitor – USA 11/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 11/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
